VerticalNews Ivy League
Welcome to VerticalNews!
RECEIVE OUR FREE NEWSLETTERON IVY LEAGUE
Chantix unsuitable for first-line smoking cessation use
November 15th, 2011
WINSTON-SALEM, N.C. - The poor safety profile of the smoking-cessation drug varenicline (Chantix™) makes it unsuitable for first-line use, according to a study published in the Nov. 2 edition of the journal PLoS One, an online publication of the Public Library of Science.
Varenicline, which already carries a "black box warning" from the U.S. Food and Drug Administration (FDA), showed a substantially increased risk of reported depression or suicidal behavior compared to other smoking-cessation treatments, according to researchers at Wake Forest Baptist Medical Center, the Institute for Safe Medication Practices, Harvard Medical School and Johns Hopkins University...
Click here for more articles from Depression
Source: VerticalNews Ivy League (2011-11-15)